Carly Brittingham, PA
Medical · Ocean City, MDNPI 1023597598
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novo Nordisk at 28.9% of the total. Reporting peaked in 2022 at $257 and has fallen 87.3% since, to $33 in 2025. That places this record below the midpoint for medical clinicians in MD, where the typical reported total is $346.
Across 24 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$115
- Lilly USA, LLC$53
- Johnson & Johnson$47
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$34
- Merck$31
- Amgen$30
- plus $87 from 5 others
What the payments were for
- Food & beverage$397100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $115 |
| Lilly USA, LLC | 3 | $53 |
| Johnson & Johnson | 3 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $34 |
| Merck | 2 | $31 |
| Amgen | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Pfizer | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$397 in reported general payments places this provider in the 50th percentile of 543 medical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $456 |
| Azithromycin | 49 | $207 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $143 |
| Methylprednisolone | 23 | $142 |
| Doxycycline Hyclate | 12 | $60 |
Paid to pharmacies, not to this prescriber.
Other medical in Ocean City
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
- Megan PayneLutherville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.